Multi-country Studies on the Effect of Positional Distribution of Fatty Acids at the Triglyceride Backbone of Vegetable Oils on Fat Deposition and Selected Health Outcome Measures - Malaysia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 102
- 主要终点
- Change of liver fat content
研究概览
简要总结
There is existing evidence to show that vegetable oils having unsaturated fatty acids in the sn-2 position with predominantly palmitic acid (C16:0) or stearic acid (C18:0) in the sn-1 and sn-3 positions of fat molecules do not raise serum cholesterol levels. These observations have come to be known as or explained by the "sn-2 hypothesis". New evidence have also emerged to show that saturated fatty acids (C16:0, C18:0) in the sn-1 and -3 positions reduces fat deposition in a rat model. Therefore, further studies in humans are warranted to confirm these earlier findings.
Fats and oils are made up of >90% triacylglycerol (TAG)- fat molecules which consist of a glycerol backbone to which 3 esterified fatty acids are attached. The positions of fatty acid attachment are referred to by stereospecific numbers, sn -1, -2 and -3. Early evidence shown that the unique stereospecificity of fatty acid distribution on the palm fat molecule conferred health benefits in that it inhibited experimental atherosclerosis in the rabbit model.
In vegetable oils, oleic acid [a monounsaturated fatty acid (MUFA)] is predominantly situated at the sn-2 position, while in animals fats it is predominantly palmitic acid or stearic acid (C16:0 or C18:0-saturated fat) that is situated there. Even though palm olein and lard have similar proportions of saturated fatty acid (SFA), MUFA and polyunsatuared fatty acid (PUFA), they differ significantly in their positional distribution on the TAG molecule. Palm olein TAG contains only 7-11 % palmitic acid at the sn-2 position while about 87% is unsaturated fatty acids (oleic acid and linoleic acid). Lard has the highest amount of palmitic acid in the sn-2 position at 70%. On the other hand, in human milk, palmitic acid is predominantly in sn-2 (53-57 %) while cow milk fat contains less palmitic acid (38 %) there. It is now believed that the distribution of fatty acids in the TAG is more important than the fatty acid composition alone in conferring the oils' 'saturated' or 'unsaturated' properties.
In this proposed study, the effects on the outcome measures investigated of different fatty acids (palmitic acid, oleic acid, linoleic acid) at the sn-1, sn-2 and sn-3 positions of the TAG molecule in three different test fats will be investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male or female, aged 20-60 years
- •BMI 18-5-27.5 kg/m2
排除标准
- •History of any one of these chronic diseases - type 2 DM, hypertension, coronary heart disease, hyperlipidemia, liver disease, cancer
- •Current problem with indigestion or constipation or bowel movement
- •On medication/nutraceutiucals to reduce blood lipids or blood pressure or weight
- •Pregnant or lactating women or taking COCP
- •Habitual smokers (>2 sticks per day)
- •Alcoholism (>21 units per week for men & >14 units per week for women)
- •Mean screening blood pressure >140/90 mmHg
- •Screening TC>6.2 mmol/L or TAG >2.0 mmol/L
- •Planned trip abroad/overseas during period of study
- •Unable to adhere to at least 90% of the prescribed oil & recommended energy and fat per day per research protocol
结局指标
主要结局
Change of liver fat content
时间窗: week 0 (baseline) and week 16
measured by magnetic resonance imaging (MRI) scan
次要结局
- Change of body mass index (BMI)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of visceral adiposity index (VAI)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum total cholesterol (TC)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum lipoprotein ration (TC/HDLC)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of visceral adipose tissue(week 0 (baseline) and week 16)
- Change of serum Apolipoprotein A(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of waist circumference(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of body fat distribution/content(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of body adiposity index (BAI)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum Apolipoprotein B(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum Lp (a)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Faecal fatty acid composition (FAC)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Systolic and diastolic blood pressure(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum leptin(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum low-density lipoprotein (LDLC)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum tumor necrosis factor alpha (TNF-α)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum high-density lipoprotein cholesterol (HDLC)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum HDL-subfractions(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum triacylglycerie (TAG)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum LDL-subfractions(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of subcutaneous adipose tissue(week 0 (baseline) and week 16)
- Change of serum interleukin-6 (IL-6)(week 0 (baseline), week 4, week 8, week 12 and week 16)
- Change of serum high-sensitivity C-reactive protein (hsCRP)(week 0 (baseline), week 4, week 8, week 12 and week 16)
